Nicholas Raccagni: Heparin for VTE Prevention After Traumatic Brain Injury
Nicholas Raccagni, Biomedical Research Trainee at Virgilio Program, Neurosurgery Internship at Fondazione IRCCS Istituto Neurologico Carlo Besta (Milan, Italy), shared a post on LinkedIn about a recent article he and his colleges co-authored, published in Neurosurgery, adding:
“Venous thromboembolism prophylaxis after traumatic brain injury sits at the intersection of thrombosis prevention and hemorrhagic risk.
In our recent article in Neurosurgery, we compared low-molecular-weight heparin and unfractionated heparin in adults with TBI, synthesizing the available direct comparative evidence and examining the consistency of observed associations across TBI phenotypes.
Our findings point to a clinically relevant signal, but one that remains difficult to disentangle from treatment selection and residual confounding present within the entirely retrospective evidence base.
Prospective studies are needed to determine whether this signal is causal and how it should inform thromboprophylaxis in TBI.
I am especially grateful to Leonardo Di Cosmo and Ismail Zaed for their close collaboration throughout this project, and to all my co-authors for their contributions.”
Title: Low-Molecular-Weight Heparin Versus Unfractionated Heparin for Venous Thromboembolism Prophylaxis in Adult Traumatic Brain Injury: A Systematic Review and Meta-Analysis
Authors: Nicholas Giulio Raccagni, Leonardo Di Cosmo, Marco Dotti, Filippo Emanuele Colella, Sofia Carmelini, Ismail Zaed
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A
-
Oct 16, 2026, 12:40Edward Lee Carter: How Factor XI Inhibition Could Transform Anticoagulation Therapy
-
Oct 16, 2026, 12:40Marc Carrier: Looking Ahead to ISTH 2027 in Vancouver
-
Oct 16, 2026, 12:30Bob Lempke: How One Blood Donation Can Save Up to Three Lives
-
Oct 16, 2026, 12:30Why VWF Therapies Belong on the EU Critical Medicines List – EHC
-
Oct 16, 2026, 12:17Exploring Endothelial Cells, Genetic Fate Mapping, and Revascularization – ISTH